Get to know our clinical trials
Study of GEN3013 in patients with relapsed, progressive, or refractory B-lymphocyte lymphomaStudy of GEN3013 in patients with relapsed, progressive, or refractory B-lymphocyte lymphoma
THE PURPOSE OF THIS TRIAL IS TO INVESTIGATE THE SAFETY AND TOLERABILITY OF GEN3013 IN PATIENTS WITH DIFFERENT SUBTYPES OF B-LYMPHOMA. THIS TRIAL WILL ALSO MEASURE BLOOD LEVELS OF GEN3013 AND LOOK AT HOW THE BODY PROCESSES AND ELIMINATES GEN3013.
Technical Summary
- PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY OF GEN3013 IN PATIENTS WITH RELAPSED, PROGRESSIVE, OR REFRACTORY B-LYMPHOCYTE LYMPHOMA
- Code EudraCT: 2017-001748-36
- Protocol number: GCT3013-01
- Promoter: Genmab A/S
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.